Myotonic Dystrophy Drug Pipeline Landscape Report 2024 Featuring AMO Pharma, Harmony Biosciences, Entrada Therapeutics, Arrowhead Pharmaceuticals, Arthex Biotech, NeuBase Therapeutics, and Enzerna
01 mars 2024 08h49 HE
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Myotonic Dystrophy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Myotonic Dystrophy- Pipeline...